Palisade Bio Reports First Quarter 2023 Financial Results
May 12, 2023 08:05 ET
|
Palisade Bio, Inc.
Company has sufficient cash expected to fund operations through 2024 Carlsbad, CA, May 12, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a...
Palisade Bio Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study
May 11, 2023 09:05 ET
|
Palisade Bio, Inc.
Study designed to determine if a different dosing protocol for all indications might enhance the risk profile of LB1148 while simultaneously providing efficacy Company expects enrollment to be...
Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-K
April 26, 2023 12:15 ET
|
Aridis Pharmaceuticals, Inc.
LOS GATOS, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, announced today that it received a notice...
Vallon Pharmaceuticals Adjourns Special Meeting of Stockholders Until April 20, 2023
April 12, 2023 16:05 ET
|
Vallon Pharmaceuticals Inc.
Board of Directors unanimously recommend Vallon stockholders to vote “FOR” all proposals outlined in the Company’s definitive Proxy Statement (the “Proxy”) in order to close the proposed merger with...
Palisade Bio Receives Canadian Patent Covering Composition of Lead Program in Development, LB1148
April 06, 2023 09:00 ET
|
Palisade Bio, Inc.
Carlsbad, CA, April 06, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...
Palisade Bio Announces Enrollment of First Patient in Newsoara Phase 3 Clinical Trial Evaluating LB1148
April 05, 2023 08:35 ET
|
Palisade Bio, Inc.
Enrollment triggers milestone payment Carlsbad, CA and Shanghai, China, April 05, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a...
Aeterna Zentaris Provides Update on Macrilen® (Macimorelin), Reiterates Advancement of Pediatric DETECT Trial
April 05, 2023 07:55 ET
|
Aeterna Zentaris Inc
U.S. sales of Macrilen® for adult use to be temporarily discontinued as of May 23, 2023, while DETECT trial continues in order to expand the opportunity for pediatric usage of Macrilen®Sales and...
Vallon Pharmaceuticals Provides an Update on Proxy Voting for the Proposed Merger with GRI Bio and Urges Stockholders of Record as of March 6, 2023 to Vote by April 11, 2023, at 11:59 PM ET
April 04, 2023 09:00 ET
|
Vallon Pharmaceuticals Inc.
Over 90% of the shares voted to date have shown support “FOR” each of the five proposals, but additional votes are needed in order to close the proposed merger with GRI Bio PHILADELPHIA, PA,...
Palisade Bio Announces $6 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules
April 03, 2023 08:30 ET
|
Palisade Bio, Inc.
Carlsbad, CA, April 03, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is...
Aridis Provides Corporate Update
March 31, 2023 19:00 ET
|
Aridis Pharmaceuticals, Inc.
LOS GATOS, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today announced a corporate update on...